Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 639-647 |
| Number of pages | 9 |
| Journal | European Heart Journal |
| Volume | 38 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2017 |
Fingerprint
Cite this
Percutaneous tricuspid valve therapies: The new frontier. / Taramasso, M; Pozzoli, Alberto; Guidotti, Andrea; Nietlispach, F; Inderbitzin, DT; Benussi, S; Alfieri, O; Maisano, F.
In: European Heart Journal, Vol. 38, No. 9, 2017, p. 639-647.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Percutaneous tricuspid valve therapies: The new frontier
AU - Taramasso, M
AU - Pozzoli, Alberto
AU - Guidotti, Andrea
AU - Nietlispach, F
AU - Inderbitzin, DT
AU - Benussi, S
AU - Alfieri, O
AU - Maisano, F
PY - 2017
Y1 - 2017
N2 - Moderate-to-severe tricuspid regurgitation (TR) affects 1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreated patients with significant TR. Therefore, there is a large unmet clinical need for patients with severe TR who are not referred for conventional surgery, mainly due to expected high surgical risk. Percutaneous procedures are an attractive alternative to surgery for patients deemed to be high-risk surgical candidates. Whereas over the past few years, the development and clinical use of percutaneous approaches to the aortic valve and mitral valve have been widespread, few data are available about the feasibility and the efficacy of the percutaneous tricuspid valve treatment. This review will explore the available technologies, which are today under evaluation and the preliminary clinical results. © The Author 2016.
AB - Moderate-to-severe tricuspid regurgitation (TR) affects 1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreated patients with significant TR. Therefore, there is a large unmet clinical need for patients with severe TR who are not referred for conventional surgery, mainly due to expected high surgical risk. Percutaneous procedures are an attractive alternative to surgery for patients deemed to be high-risk surgical candidates. Whereas over the past few years, the development and clinical use of percutaneous approaches to the aortic valve and mitral valve have been widespread, few data are available about the feasibility and the efficacy of the percutaneous tricuspid valve treatment. This review will explore the available technologies, which are today under evaluation and the preliminary clinical results. © The Author 2016.
U2 - 10.1093/eurheartj/ehv766
DO - 10.1093/eurheartj/ehv766
M3 - Article
VL - 38
SP - 639
EP - 647
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 9
ER -